Dose and age matter: Xylazine prevents age-dependent fentanyl lethality in rats

Xylazine, a veterinary sedative not approved for human use, has emerged as a common adulterant in North America's illicit opioid supply, e.g., detected in over 90% of Philadelphia's street samples. Preclinical studies of fentanyl-xylazine interactions have employed widely varying dose ratios, making it difficult to draw conclusions relevant to real-world exposures.

Using an epidemiologically-relevant ratio derived from Philadelphia's drug supply (~1:3 fentanyl:xylazine), we administered fentanyl alone (0.56mg/kg, i.p.) or fentanyl-xylazine combination (0.56mg/kg + 1.78mg/kg) to drug-naive Sprague-Dawley rats at two ages: young adults (9 weeks, n =  8/group) and adults (16 weeks, n =  8/group). Plasma fentanyl concentrations were measured at 15- and 60- min post-administration.

In 9-week-old rats, fentanyl alone produced 75% mortality (100% males, 50% females), whereas the fentanyl-xylazine combination resulted in zero mortality (p = 0.0023). Xylazine alone produced no adverse effects. In 16-week-old rats, neither treatment caused mortality, revealing age-dependent vulnerability. Pharmacokinetic analysis showed xylazine co-administration reduced plasma fentanyl concentrations 8-fold at 15min, with apparent pattern reversal by 60min, consistent with delayed absorption.

At an epidemiologically-relevant 1:3 ratio, xylazine completely prevented fentanyl mortality in young animals. These data, along with emerging clinical evidence, suggest fentanyl-xylazine interactions are more complex than current models predict. While xylazine contamination remains a serious public health concern, understanding actual toxicological interactions at real-world ratios is essential for evidence-based harm reduction and policy responses.